Sonomind secures €3 million to advance its novelneuromodulation ultrasound device and opens a new therapeuticpathway in psychiatry and neurology

Updated: Dec 3, 2025

Paris, France, September 24, 2025 – Sonomind, a company developing a unique

medical device for non-invasive, personalized ultrasound-based brain stimulation,

today announces a €3 million ($3.53M) fundraising, including €2 million ($2.35M) in

seed capital from Critical Path Ventures. It has also secured support from the French

Government as part of the France 2030 initiative, benefitting from €1 million ($1.18M)

in non-dilutive funding awarded through Bpifrance Deeptech development aid.

The funding will enable Sonomind, founded in 2024, to accelerate the development of

its personalized therapy platform based on low-intensity ultrasound. The company

plans to begin clinical trials within the next few months to evaluate its technology in

the treatment of drug-resistant depression.

“This funding demonstrates the continued confidence of our investors in Sonomind’s

vision, technology, and our capacity to bring new therapeutic solutions to psychiatry

and neurology. We are truly grateful for their ongoing support,” said Jeremy Bercoff,

physicist, co-founder and president of Sonomind. “This brings us one step closer to our

mission of providing an effective treatment for the millions of people living with

depression—transforming a lifelong struggle into a renewed chance at life. Our

ambition is to enable rapid, precise and side-effect-free treatment.”

Sonomind’s ultrasound-based, non-invasive neuromodulation technology has shown

encouraging initial results in a first clinical feasibility study conducted to evaluate this

technology on a small group of patients with severe depression. These initial results

have been published in the Brain Stimulation Journal, where treatment was given over

five consecutive days. Excellent tolerance and an average reduction of more than 60%

in the severity of depression on the fifth day of the protocol were reported, and without

any serious adverse events.

Depression affects 330 million people worldwide, according to the WHO, and remains

the leading cause of disability. Approximately 30% to 50% of cases of depression are

classified as resistant to medication.

Sonomind’s innovation is based on more than 25 years of research at the Institute of

Physics for Medicine (a joint research unit involving Inserm, ESPCI Paris – PSL, and

CNRS), led by company co-founders Professors Mickael Tanter and Jean-François Aubry.

The ultrasound waves are delivered through an acoustic lens that is custom designed

for each patient. Sonomind’s unique innovation allows ultrasound waves to pass

through the skull, compensating for skull thickness variations and enabling accurate

targeting of deep brain structures in order to treat neuropsychiatric disorders.

“Sonomind is developing a truly groundbreaking innovation in psychiatry, backed by

two decades of research at prestigious academic institutions and driven by an

exceptional team of ultrasound and medtech specialists,” said Nicolas Foessel, CEO of

Critical Path Ventures. “This approach was instrumental in our choice to support

Sonomind. Mental health remains one of the world’s most pressing public health

concerns, representing a market valued at $500 billion, where treatment resistance

continues to be a significant challenge.”